J. David Peske

A DNA vaccine targeting Mtb persisters reduces TB treatment duration in mice and elicits similar immune responses in macaques.

This paper develops an anti-CCRL2 antibody-drug conjugate (ADC) that shows potent cytotoxicity against high-risk MDS/AML cells without harming healthy hematopoietic cells.

This study shows that targeting CCRL2 with an antibody-drug conjugate improves TB treatment in mice by reducing inflammation and enhancing immune responses.